$70 Million

Avedro, Inc.

Initial Public Offering

Co-Manager, February 2019

Avedro, Inc.
Avedro is a commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision. Avedro's proprietary Corneal Remodeling Platform uses corneal cross-linking to strengthen, stabilize and reshape the cornea and performs minimally invasive and non-invasive outpatient procedures to treat corneal ectatic disorders and correct vision for conditions such as presbyopia and low myopia. The platform is comprised of two medical devices, the KXL and Mosaic Systems, which deliver UVA light and a suite of proprietary single-use riboflavin drug formulations that induce a biochemical reaction called corneal cross-linking when applied to the cornea